The proposed $9.4 billion merger between Rite Aid and Walgreens faces increasing scrutiny from the Federal Trade Commission. Rite Aid CEO John Standley has criticized what he says is a drawn-out regulatory process but has also admitted that the uncertainty around the deal is taking a hit on the pharmacy and drug store chain’s business. In a recent letter to employees, Standley seemed to imply that Rite Aid is mulling how to proceed if the deal falls through.
Looking for leads, investment insights, or competitive intelligence?
News about Rite Aid
The packets have a solution that neutralizes opioids.
The 2018 flu season is deadly. But you can still get your flu vaccine—in many cases, for free.
Another mega deal could be cooking for the drugstore giant.
It's going to be even worse than 2008, research shows